MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Sunshine Biopharma Inc. (SBFM)

Sunshine Biopharma Inc. (SBFM)

|||

Cash Flow Overview

Change in Cash
$6,881,088
Free Cash flow
-$924,992
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from public offering
    • Exercise of warrants
    • Inventory
    • Others
Negative Cash Flow Breakdown
    • Net (loss)
    • Deposits
    • Accounts payable & accrued expen...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents at beginning of period
-
-
-
9,686,529
Net (loss)
-1,564,048
-1,243,869
-2,140,927
-883,820
Depreciation and amortization
77,974
76,859
98,581
96,163
Intangible assets impairment
-
-
131,788
554,650
Disposal of tangible assets
-
-
7
10,250
Intangible asset impairment
0
-
-
-
Stock issued for services
96,900
-
0
0
Accounts receivable
88,610
609,601
-41,293
649,850
Inventory
-793,996
-78,399
-772,796
1,286,164
Deposits
209,740
71,740
-
-
Prepaid expenses
-133,703
-154,726
-189,082
-36,168
Reduction in right-of-use asset
-
-
-
-147,016
Right-of-use asset
-
-
-109,434
-
Reduction in right-of-use asset
49,977
52,788
-
-
Accounts payable & accrued expenses
-156,687
-455,836
-565,040
1,224,786
Lease liability
-51,267
-54,001
-57,782
-129,741
Earn-out payable
-
-
0
0
Income tax payable
-175
175
-152,874
162,992
Net cash (used in) operating activities
-917,977
-2,072,100
-1,616,006
-727,800
Purchase of intangible assets
-1,895
99,389
40,998
26,103
Purchase of equipment
7,015
5,129
-1,039
8,040
Net cash (used in) investing activities
-5,120
-104,518
-50,209
-118,295
Proceeds from public offering
5,085,000
-
0
0
Exercise of warrants
2,719,185
0
724,500
0
Purchase of treasury stock
-
-
0
0
Net cash provided by financing activities
7,804,185
0
724,500
75,536
Net increase (decrease) in cash and cash equivalents
6,881,088
-2,176,618
-941,715
-770,560
Foreign currency translation adjustment
-176,642
-
-
97,165
Cash and cash equivalents at end of period
13,748,301
-
-
9,306,438
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from publicoffering$5,085,000 (178.08%↑ Y/Y)Exercise of warrants$2,719,185 (23.86%↑ Y/Y)Net cash provided byfinancing activities$7,804,185 (97.66%↑ Y/Y)Net increase(decrease) in cash and cash...$6,881,088 (2246.06%↑ Y/Y)Canceled cashflow$923,097 Inventory-$793,996 (-170.65%↓ Y/Y)Prepaid expenses-$133,703 (47.68%↑ Y/Y)Stock issued forservices$96,900 Depreciation andamortization$77,974 (-43.22%↓ Y/Y)Reduction in right-of-useasset$49,977 (152.94%↑ Y/Y)Purchase of intangibleassets-$1,895 (-100.32%↓ Y/Y)Net cash (used in)operating activities-$917,977 (69.27%↑ Y/Y)Net cash (used in)investing activities-$5,120 (99.23%↑ Y/Y)Canceled cashflow$1,152,550 Canceled cashflow$1,895 Net (loss)-$1,564,048 (46.99%↑ Y/Y)Purchase of equipment$7,015 (-95.81%↓ Y/Y)Deposits$209,740 Accounts payable &accrued expenses-$156,687 (81.56%↑ Y/Y)Accounts receivable$88,610 (118.00%↑ Y/Y)Lease liability-$51,267 (-167.87%↓ Y/Y)Income tax payable-$175 (98.27%↑ Y/Y)